Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

NCT Number	NCT07085182
Lead Sponsor	Zibo Municipal Hospital
Conditions	NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
Enrollment	20 participants
Start Date	2024-01-13
Primary Completion	2027-12-10 (estimated)
Study Completion	2028-12-10 (estimated)
Updated on ClinicalTrials.gov	2025-07-25